Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04022213 · ClinicalTrials.gov registry record · Phase 2
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
A Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04022213 is a Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04022213, a Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.
Conditions Studied
Interventions
- DRUG 131 I-omburtamab
- RADIATION WAP-IMRT
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04022213
The ClinicalTrials.gov registry entry for NCT04022213 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Peritoneal Cancer appearing as the primary indexed condition, and to 2 interventions - of which 131 I-omburtamab is the first listed.
NCT04022213 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04022213 about?
NCT04022213 is a clinical study titled "A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum". The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in th...
What is the current status of trial NCT04022213?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-07-15. Estimated completion is 2026-07.
What conditions does trial NCT04022213 study?
This clinical trial studies the following conditions: Peritoneal Cancer, Desmoplastic Small Round Cell Tumor, Peritoneal Carcinoma.
What interventions are being tested in trial NCT04022213?
The interventions under investigation include: 131 I-omburtamab (DRUG), WAP-IMRT (RADIATION).
Who is sponsoring clinical trial NCT04022213?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04022213 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.